Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
2020 was another year of strong deliver and growth for UCB. We kept our pipeline on track. Read our latest financial results https://t.co/ym9jplmMq2 https://t.co/IoixpCqmUy
— UCB News (@ucb_news) 25.02.2021 -
We’re collaborating with Microsoft to accelerate the development of life-changing therapies for people living with severe diseases. Read about our new strategic collaboration https://t.co/ryEPCEAIb6 https://t.co/SxNlIym13T
— UCB News (@ucb_news) 23.02.2021 -
The #BCGstrategycup is entering the semi-final stage. Yesterday students learned how UCB recognizes that digital technology is changing the way patients experience their care & how healthcare professionals practice medicine. Find out more here: https:
— UCB News (@ucb_news) 23.02.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
